CJC-1295 + Ipamorelin Blend: Dual-Pathway Research Guide

The CJC-1295 no DAC 5 mg + IPA 5 mg blend is a two-component research mixture combining a modified GHRH(1-29) analog (CJC-1295 No DAC) with the selective ghrelin-receptor agonist ipamorelin (IPA). The two components engage complementary pituitary signaling routes: GHRHR/Gs-cAMP and GHS-R1a/Gq-calcium, which published secretagogue reviews describe as the mechanistic basis for additive growth-hormone (GH) release in laboratory models. This guide focuses on study design for mixtures, component-level quality control, and the limits of the published evidence; it is prepared for laboratory research purposes only. The blend is not approved for human or veterinary use, not a medicine, and no disease-treatment claim or self-administration regimen is provided.

What the Blend Contains

The catalog entry CJC-1295 no DAC 5mg + IPA 5mg describes a two-component peptide research mixture with a nominal 1:1 labeled-mass ratio. The ipamorelin component has the reported sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 (CAS 170851-70-4; computed average molecular mass near 711.9 g/mol), while the modified GRF component is an amidated GHRH(1-29)-family analog without an albumin-binding DAC group. Product documentation correctly warns that component content in a mixture is lot-specific and should be verified separately: a single HPLC area percentage does not establish the identity or quantity of both peptides.

Why Two Receptor Pathways Are Modeled Together

A review of GH secretagogues in body-composition research summarizes the signaling split: GHRH analogs activate GHRHR through Gs-coupled adenylyl cyclase/cAMP, supporting GH synthesis and pulsatile release, while ghrelin-mimetic peptides activate GHS-R1a through Gq/11-coupled phospholipase-C/IP3 calcium release [1]. Because somatotrophs express both receptors, combined stimulation can recruit both signaling arms; this is the rationale researchers test in controlled models rather than a guarantee of any net effect.

Ipamorelin’s selectivity profile is the second design element. It was characterized as the first GHS-R1a agonist with selectivity for GH release similar to GHRH, showing no meaningful ACTH or cortisol rise even at doses more than 200-fold above the GH-release ED50 [2]. In a mixture study, that selectivity reduces one source of confounding compared with first-generation GHRPs, although cortisol and prolactin should still be measured directly.

Study Design for a Two-Component Mixture

Mixture experiments differ from single-agent assays in three practical ways. First, factorial controls are required: vehicle, component A alone, component B alone, and the combination, so that synergy can be distinguished from simple addition. Second, endpoints should span the axis: serial GH for pulse kinetics, IGF-1 for cumulative exposure, and off-hormone markers (cortisol, prolactin, glucose) because each component carries a different risk profile. Third, timing matters: the GHRH analog and GHS-R1a agonist have different reported durations, and sampling windows should reflect both rather than a single peak assumption.

Native GHRH itself clears within minutes after injection [3], and modified no-DAC analogs remain short-acting relative to albumin-bound variants; this favors pulse-timed sampling designs. Published numerical values for either component belong to their original studies and are not a protocol for this mixture.

Quality Control Specific to Blends

Single-agent QC rules understate the risk in mixtures. Request, per lot: separate identity data for each component (sequence or peptide mapping, intact mass); component-specific content or ratio verification; HPLC purity per component where feasible; net peptide content versus total powder mass; acetate/salt documentation; endotoxin; residual solvents; and storage stability under the chosen diluent. Reconstitution should follow the batch CoA, use sterile technique, and record solvent, concentration, preparation date, and storage history so that preparation variation is not mistaken for biological variation.

Researchers may also order the components separately for side-by-side controls: CJC-1295 No DAC and Ipamorelin.

Evidence Boundaries and Safety Notes

The peer-reviewed literature supports the mechanistic plausibility of GHRH-plus-secretagogue co-stimulation, but dedicated controlled trials of this exact commercial blend are absent; published combination data come from separate compounds, species, and designs. Reported safety considerations for the class include injection-site reactions, flushing, transient head pressure, water-retention signals, and potential glucose changes; chronic-use data remain limited. All work requires institutional biosafety and animal-care approval, and anti-doping rules prohibit secretagogue use in competitive sport.

Molecular Fundamentals: Two Different Peptide Architectures

CJC-1295 is a modified growth-hormone-releasing hormone analogue based on the first 29 residues of GHRH, with a maleimide linker that allows covalent attachment to albumin. Ipamorelin is a short pentapeptide growth-hormone secretagogue that acts through the ghrelin receptor (GHSR1a). The two molecules share no sequence homology and bind different receptors, which is the entire rationale for studying them together.

That difference also determines what each contributes to a co-culture or in vivo model. GHRH analogues act upstream on pituitary somatotrophs; ghrelin-receptor agonists act through a separate G-protein-coupled pathway. A combination experiment that measures only total GH cannot distinguish which receptor arm produced the change, so receptor-proximal readouts or selective antagonists are useful controls.

Pharmacology: Half-Life, Pulsatility and Receptor Selectivity

The DAC modification changes the pharmacokinetic profile substantially. Without the albumin-binding linker, the GHRH analogue has a short circulating half-life; with it, reversible binding to albumin extends exposure and produces a sustained rather than pulsatile signal. Ipamorelin’s half-life is short by comparison. In a mixture, this mismatch means the two components are not at their peak at the same time, which matters for sampling schedules.

Preclinical literature describes ipamorelin as relatively selective for GH release compared with earlier secretagogues, with less reported activation of ACTH and cortisol pathways. That description comes from specific animal and cell models and should be re-tested rather than assumed in a new system. Receptor selectivity is a property measured under defined conditions, not a fixed label.

For a combination study, report the matrix, the sampling time points relative to each component’s exposure curve, and the assay used for each hormone. Pooling time points into a single aggregate hides the mismatch that the DAC modification creates.

Frequently Asked Questions

Q1: What is in the CJC-1295 no DAC 5mg + IPA 5mg blend?

A modified GHRH(1-29) analog (CJC-1295 No DAC) plus ipamorelin, a GHS-R1a agonist, at a nominal 1:1 labeled-mass ratio per lot documentation.

Q2: Why pair a GHRH analog with a ghrelin agonist?

The components use complementary signaling (GHRHR/Gs-cAMP versus GHS-R1a/Gq-calcium), which published reviews identify as the basis for testing additive GH release in controlled models [1].

Q3: Does one HPLC purity number verify both peptides?

No. A mixture needs component-level identity and content verification; a single chromatographic area percentage cannot confirm both molecules [1].

Q4: What controls should a blend experiment include?

Vehicle, each component alone, and the combination, with GH, IGF-1, and off-hormone markers such as cortisol and prolactin measured across time.

Q5: Is ipamorelin selective for GH release?

Published characterization found minimal ACTH/cortisol effects even at high multiples of the GH-release threshold, though direct measurement remains necessary [2].

Q6: What documentation should accompany the blend?

Per-component identity, ratio/content data, purity, net peptide content, salt form, endotoxin, residual solvents, and storage instructions on the signed CoA.

Q7: Is this blend approved for clinical use?

No. It is a laboratory research mixture; it is not a medicine, not for human or veterinary administration, and no treatment claim is made.

Research Material CTA

View the blend: CJC-1295 no DAC 5mg + IPA 5mg · components: CJC-1295 No DAC · Ipamorelin Batch-level HPLC reporting, lab-tested CoA traceability, and worldwide tracked shipping for qualified research buyers. Research use only; verify current lot documentation before assay setup.

Sources

  1. Beyond the androgen receptor: growth hormone secretagogues in body-composition research (review). https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/
  2. Ipamorelin, the first selective growth hormone secretagogue. https://pubmed.ncbi.nlm.nih.gov/9849822/
  3. Growth Hormone Doping in Sports: A Critical Review (Endocrine Reviews 2012; native GHRH pharmacokinetics). https://academic.oup.com/edrv/article-pdf/33/2/155/8858256/edrv0155.pdf


The Ipamorelin compound data file collects the sequence, molecular weight, CAS and the impurity routes worth watching for this compound on one page.

Leave a Reply

Your email address will not be published. Required fields are marked *